News from Mayo Clinic

Mayo Clinic Laboratories and Progentec Diagnostics Launch Lupus Advanced Biomarker Testing Services

Newswise — ROCHESTER, Minn. and OKLAHOMA CITY — As a successful outcome of the collaboration announced in 2023 between Mayo Clinic Laboratories, a leading global reference laboratory, and Progentec Diagnostics, a digital health and biomarker technology-based company focused on autoimmune conditions, Progentec’s proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are available. These tests, known as the DX Lupus Disease Activity Index and the DX Lupus Flare Risk Index, are accessible to all clients of Mayo Clinic Laboratories effective April 25 for managing active disease and anticipating the onset of symptoms.

"These two tests signify the significant progress our two organizations have made in bringing new diagnostic and monitoring options to patients and their physicians," says William Morice II, M.D., Ph.D., CEO of Mayo Clinic Laboratories. "With our ongoing commitment to collaboration and innovation, we're dedicated to advancing the field of diagnostics and enhancing patient care."

"Progentec is committed to offering advanced diagnostic and monitoring options to physicians within the Mayo Clinic Laboratories ecosystem. We are excited to collaborate with Mayo Clinic Laboratories to expand the availability of these technologies and make a difference to lupus patients and their health," says Mohan Purushothaman, Ph.D., CEO of Progentec Diagnostics.

The two tests are for lupus disease management and are based on proprietary indices computed based on advanced algorithms. The aiSLE® DX Lupus Disease Activity Index is useful in identifying if patients have active disease and includes 10 biomarkers. Results from this test can also be used to help determine the frequency of care assessment, guide disease management, and evaluate if an early intervention for treatment is needed. The aiSLE® DX Lupus Flare Risk Index uses 11 biomarkers to determine the risk of onset of a lupus flare in the next 12 weeks. These tests have been developed and validated based on multiple studies and in association with leading scientists at major academic centers.

Mayo Clinic Laboratories fosters novel collaborations that drive innovative testing approaches. Through relationships with patient-centric pioneers, we offer leading-edge diagnostics that advance medical knowledge and improve patient care.

Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.


About Mayo Clinic Laboratories 
Mayo Clinic Laboratories, the global leader in turning test results into clinical answers, provides advanced testing and pathology services for 3,400 healthcare organizations in partnership with Mayo Clinic's Department of Laboratory Medicine and Pathology. Mayo Clinic Laboratories offers more than 4,400 tests and pathology services and performs more than 26 million tests annually. Revenue is used to support medical education and research at Mayo Clinic.

About Progentec
Progentec Diagnostics, Inc. is a digital health and diagnostic company focused on improving outcomes in patients with autoimmune disease, a family of complex chronic conditions that account for $150B in annual healthcare spend in the U.S. The company has brought together a suite of novel biomarker blood tests with advanced AI-based technologies that use cytokine and digital signals to provide predictive power leading to better care decisions and improved patient quality of life. Integration of digital and virtual solutions to ensure continuity of care is a major area of focus for the company.